Australia Stock Exchange release from BARD1 LIFE : Proof-of-Concept for SubB2M ELISA-Based Ovarian Cancer Test
16/08/2021 23:39
Australia Stock Exchange release from BARD1 LIFE BD1.AX : Proof-of-Concept for SubB2M ELISA-Based Ovarian Cancer Test
Recent news on Inoviq
See all newsBrief: Inoviq Posts FY26 Net Loss After Tax A$7.5 Million
Brief: INOVIQ Requests Trading Halt
Brief: INOVIQ Says Peter Gunzburg Elected To Role Of Chairman
Brief: Inoviq Says Chairman David Williams To Step Down At Year-End
Australia's INOVIQ slips to 2-1/2-month low on $6.2 million discounted placement